indevus - 500 Beiträge pro Seite

[grast]

wer hat noch indevus aktien?
auch bei ca 1 damals rein?
wie hoch schätzt ihr ein , geht es bis zur möglichen zulassung v trospium?
welche marktkap ist gerechtfertigt?
danke( falls noch einer drin ist und antwortet)

[Voltaires]

Hallo @,

IPIC feiert die 36. Auferstehung!
Der Grund kommt sicher in ein paar Tagen (FDA).

So loooooong,
V.

[grast]

ja , duarch die decke heute.
bei aktzeptablem umsatz.
in den nächsten monaten könnten wir endlich unseren seit langem fälligen gewinn ernten.
nach jahren des durstens.(zwincker)
go , baby , goooo

[Wallgrekk]

Hi Voltaires:

Erwäge seit längerem mal
wieder einen Einstieg.

Hast Du mehr News bzgl.
FDA?

Danke!

Wall

[Tadschik]

Ende April wird diese Aktie Indevus Pharmaceuticals zu einer
der heißen Biotech-Stories werden!

infos dazu:
die eigentliche Hot-story ist das Medikament Trospium.
Auf der Tagung der American Urological Association in Chicago vom 26. April bis zum 1.Mai dieses Jahres wird das Indevus-Management alle Ergebnisse der abgeschlossenen Phase-III-Studie vorstellen.
Was dann passiert, ist leichter vorherzusagen als das deutsche Wetter im Winter: Die Börse wird Indevus wieder
entdecken und das wahre Potenzial dieses vergessenen Small Caps erkennen.

Indevus hat mit Trospium Spitzenmedikament gegen Reizblase in seiner Pipeline. Das Ertragspotential liegt über 1 Mrd US$. Marktkapitalisierung zu Zeit ca 120 Mio US$.
Es wird auch ein heißer Übernahmekandidat...

schaut euch den Wert mal genauer an!

[fonx]

Hallo,habt Ihr eine WKNnr.??????? FONX

[Wallgrekk]

So, bin mal seit laaaaaaangem
wieder rein.

Ich denke, bis zur Tagung können wir noch mit einem kräftigen Kursanschub rechnen!


Cheers & ich freu mich tierisch,
wieder in diese tolle, in absolut vergessen
geratene Aktie investieren zu können!

Wall

[desastermaster]

Haben sie also ein neues Antipilzcompound einlizensiert.
Naja. Spannend wirds wenn die NDA fuer Trospium entschieden
wird.
Best
dm

Press Release for Indevus Pharmaceuticals Inc


Indevus Licenses Worldwide Rights to Anti-Fungal
Compound, Aminocandin, from Aventis
4/23/2003 8:40:00 AM
LEXINGTON, Mass., Apr 23, 2003 (BUSINESS WIRE) --
Indevus Pharmaceuticals, Inc. (IDEV) today
announced that it has licensed exclusive worldwide
rights from Aventis SA (AVE) to aminocandin, a
member of a new class of anti-fungal compounds for
the treatment of a broad spectrum of systemic,
invasive infections. The Company expects that
aminocandin will be ready for Phase 1 clinical
testing during 2003. In exchange for these rights
and for Aventis` inventory of aminocandin, Indevus
will make an up-front, licensing payment to
Aventis, as well as milestone payments and
royalties on future sales. Under this agreement,
Indevus is responsible for all development and
commercialization activities for both intravenous
and oral formulations of aminocandin on a
worldwide basis. Aventis has agreed to manufacture
the key component of aminocandin, using its
proprietary fermentation technology.

"Our acquisition of aminocandin significantly
enhances the Indevus product portfolio by adding a
product candidate in an exciting new class of
compounds called echinocandins that have the
potential to treat millions of patients who suffer
from a variety of invasive, debilitating and
life-threatening fungal infections," said Glenn L.
Cooper, M.D., chairman, president and chief
executive officer of Indevus. "We see a clear need
for innovative agents in this underserved,
widespread therapeutic category.

"Based on highly predictive pre-clinical studies
of aminocandin, we believe the profile of this
compound is very competitive with other classes of
anti-fungal agents and with other echinocandins,"
said Dr. Cooper. "We believe that Aventis has
established a comprehensive pre-clinical dossier
on aminocandin, and we plan to initiate our
development activities with aminocandin
immediately, including clinical testing with the
intravenous formulation later in 2003.

"One of the exciting features of aminocandin is
that we believe it represents the first
echinocandin with the potential to be administered
orally," said Dr. Cooper. "We plan to vigorously
pursue technological solutions related to an oral
formulation in parallel with an intravenous
clinical program. While aminocandin is an
attractive drug candidate for Indevus as an
intravenous product only, the potential for an
oral version is compelling. An oral echinocandin
could have enormous potential as prophylactic
therapy for immunocompromised patients at risk for
serious fungal infection and to extend the
long-term therapy of infected patients upon
discharge from the hospital."

Echinocandins are the first new class of
anti-fungal agents to be developed and introduced
in more than 40 years. They are designed to be
fungicidal, that is, to destroy fungi, rather than
simply to inhibit their growth, and to have
broad-spectrum activity against the fungi that
cause serious systemic infections.

According to reports from Datamonitor, Inc., an
industry market research firm, the worldwide
market for anti-fungal agents is currently valued
in excess of $4 billion, of which approximately
$2.5 billion relates to systemic, invasive fungal
infections, and is projected to grow to $6.5
billion by 2008, of which approximately one-half
is predicted to represent systemic infections.